Work

Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer

Year: 2025

Type: article

Abstract: Objective: Approximately 30% of non-small cell lung cancers will recur after surgery, highlighting a need for additional perioperative therapies. Several recent clinical trials demonstrated a reduction in non-small cell lung cancer recurrence with the use of neoadjuvant chemoimmunotherapy. Recognizing that trial results may not always be replicated in the general population, our objective was to evaluate perioperative outcomes of immunotherapy in the real-world setting. Methods: Adult patients diagnosed with clinical stage I to III non-small cell lung cancer in the National Cancer Database between 2018 and 2022 were included. Perioperative outcomes were evaluated in the following groups: neoadjuvant chemoimmunotherapy, neoadjuvant chemotherapy, or neoadjuvant chemoradiotherapy. Results: .13). Results from adjusted logistic regressions were consistent with findings of unadjusted analyses. Conclusions: Real-world outcomes suggest that the reassuring safety and impressive downstaging effect of neoadjuvant chemoimmunotherapy seen in clinical trials can be reproduced in the general population with non-small cell lung cancer. Further study to understand the impact of perioperative chemoimmunotherapy in the real-world setting is justified.

Source: JTCVS Open

DOI: 10.1016/j.xjon.2025.09.016

Authors: Giorgio Caturegli, Michael F. Kaminski, Maureen Canavan, Oluwaseun F. Ayoade, Benjamin J. Resio, Daniel J. Boffa

Institution: Yale University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,431